- Home
- PML vs RIGL Comparison
PML vs RIGL Comparison
Compare PML & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PML | RIGL |
|---|---|---|
| Founded | 2002 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 478.0M | 537.6M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | PML | RIGL |
|---|---|---|
| Price | $7.67 | $48.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $43.20 |
| AVG Volume (30 Days) | 188.0K | ★ 638.4K |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 5.65% | N/A |
| EPS Growth | N/A | ★ 2698.26 |
| EPS | N/A | ★ 6.20 |
| Revenue | N/A | ★ $282,076,000.00 |
| Revenue This Year | N/A | $65.53 |
| Revenue Next Year | N/A | $0.22 |
| P/E Ratio | ★ N/A | $7.89 |
| Revenue Growth | N/A | ★ 79.13 |
| 52 Week Low | $6.92 | $14.63 |
| 52 Week High | $9.46 | $52.24 |
Technical Indicators
Market Signals| Indicator | PML | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 37.55 | 64.29 |
| Support Level | $7.65 | $43.81 |
| Resistance Level | $7.72 | $52.24 |
| Average True Range (ATR) | 0.05 | 3.35 |
| MACD | -0.01 | -0.13 |
| Stochastic Oscillator | 20.00 | 75.13 |
Price Performance
Historical ComparisonAbout PML Pimco Municipal Income Fund II of Beneficial Interest
PIMCO Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal income tax. The fund portfolio of investments consists of investments in different sectors such as education, healthcare, and others.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.